Israel-based biopharmaceutical firm Alcobra has presented a convention to the US Food and Medication Organization (FDA) for a Stage IIb clinical preliminary of its restrictive medication up-and-comer Metadoxine Extended Delivery (MDX) for treatment of patients with Fragile X Syndrome Market(FXS), a hereditary condition that is the most inescapable single-quality reason for chemical imbalance....